Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Afatinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved afatinib for reimbursement as a monotherapy treatment option for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutation(s), as demonstrated by a validated test method.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2013-12-20 | Health Service Executive | Indication approved for reimbursement. |